In ovarian cancer, persistent STAT3 signaling has also been demonstrated to promote tumor survival, invasion, and suppression of antitumor immunity (12, 13), as well as facilitate resistance to several front-line therapeutics, such as cisplatin and paclitaxel (14–16). This evidence concerns the gene STAT3 and neoplasm.